Health First U.S. Patient Dosed in Phase 3 Prostate Cancer Study Telix Pharmaceuticals Limited has announced a significant milestone in prostate cancer diagnostics. On January 16, 2026, the first patient was dosed in the United... Editorial16 January, 2026